{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:30:21Z","timestamp":1786120221826,"version":"build-2736575974"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1097\/jcp.0b013e31822c92d4","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T15:58:34Z","timestamp":1317743914000},"page":"673-675","source":"Crossref","is-referenced-by-count":4,"title":["Memantine for Comorbid Obsessive-Compulsive Disorder and Asperger Disorder Suggests a Link in Glutamatergic Dysregulation"],"prefix":"10.1097","volume":"31","author":[{"given":"Erica B.","family":"Bernhardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelda H.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Posey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"McDougle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 7","key":"R1-28-20210128","first-page":"5","article-title":"Practice guidelines for the treatment of patients with obsessive-compulsive disorder.","volume":"164","author":"Koran","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"4","key":"R2-28-20210128","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/archpsyc.1994.03950040046006","article-title":"Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.","volume":"51","author":"McDougle","year":"1994","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"R3-28-20210128","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archpsyc.57.8.794","article-title":"A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.","volume":"57","author":"McDougle","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"R4-28-20210128","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4088\/JCP.v66n0107","article-title":"The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients.","volume":"66","author":"Connor","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"R5-28-20210128","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/JCP.0b013e318192e9a4","article-title":"Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.","volume":"29","author":"Aboujaoude","year":"2009","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"R6-28-20210128","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/JCP.0b013e3181c856de","article-title":"A single-blinded case-control study of memantine in severe obsessive-compulsive disorder.","volume":"30","author":"Stewart","year":"2010","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"R7-28-20210128","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1517\/14728214.2010.487860","article-title":"Emerging drugs for the treatment of symptoms associated with autism spectrum disorders.","volume":"15","author":"Wink","year":"2010","journal-title":"Expert Opin Emerg Drugs"},{"issue":"1","key":"R8-28-20210128","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00213-006-0518-9","article-title":"A retrospective study of memantine in children and adolescents with pervasive developmental disorders.","volume":"191","author":"Erickson","year":"2007","journal-title":"Psychopharmacology"},{"issue":"5","key":"R9-28-20210128","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1089\/cap.2006.16.517","article-title":"A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders.","volume":"16","author":"Owley","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"9","key":"R10-28-20210128","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/00004583-200009000-00008","article-title":"Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine.","volume":"39","author":"Rosenberg","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R11-28-20210128","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2005.04.043","article-title":"Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.","volume":"58","author":"Coric","year":"2005","journal-title":"Biol Psychiatry"},{"issue":"8","key":"R12-28-20210128","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.biopsych.2006.12.020","article-title":"d-Cycloserine augmented exposure therapy for obsessive-compulsive disorder.","volume":"62","author":"Kushner","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"3","key":"R13-28-20210128","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1037\/a0016402","article-title":"The combined effects of memantine and fluoxetine on an animal model of obsessive compulsive disorder.","volume":"17","author":"Wald","year":"2009","journal-title":"Exp Clin Psychopharmacol"},{"issue":"1","key":"R14-28-20210128","first-page":"512","article-title":"Riluzole for affective and behavioral disturbance in autism.","volume":"24","author":"Wachtel","year":"2009","journal-title":"Eur Psychiatry"},{"key":"R15-28-20210128","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1176\/appi.ajp.161.11.2115","article-title":"A pilot study of d-cycloserine in autistic disorder.","volume":"161","author":"Posey","year":"2004","journal-title":"Am J Psychiatry"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004714-201110000-00028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:28:09Z","timestamp":1786048089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-201110000-00028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31822c92d4","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}